THERASCREEN KRAS RGQ PCR KIT

Somatic Gene Mutation Detection System

FDA Premarket Approval P110027

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the therascreen kras rgq pcr kit, which is to be used as a companion diagnostic for the drug vectibix (panitumumab). This device is indicated for:the therascreen kras rgq pcr kit is a real-time qualitative pcr assay used on the rotor-gene q mdx instrument for the detection of seven somatic mutations in the human kras oncogene, using dna extracted from formalin-fixed paraffin-embedded (ffpe), colorectal cancer (crc) tissue. The therascreen kras rgq pcr kit is intended to aid in the identification of crc patients for treatment with erbitux (cetuximab) and vectibix (panitumumab) based on a kras no mutation detected test result.

DeviceTHERASCREEN KRAS RGQ PCR KIT
Classification NameSomatic Gene Mutation Detection System
Generic NameSomatic Gene Mutation Detection System
ApplicantQIAGEN MANCHESTER LTD
Date Received2011-07-25
Decision Date2014-05-23
Notice Date2014-06-10
PMAP110027
SupplementS
Product CodeOWD
Docket Number14M-0726
Advisory CommitteePathology
Expedited ReviewNo
Combination Product No
Applicant Address QIAGEN MANCHESTER LTD skelton House lloyd Street North manchester M15 6
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P110027Original Filing
S015 2022-06-15 30-day Notice
S014 2022-05-19 Special (immediate Track)
S013
S012 2021-02-10 Panel Track
S011 2020-03-04 30-day Notice
S010 2018-03-08 30-day Notice
S009 2015-08-18 Normal 180 Day Track No User Fee
S008 2015-02-18 Normal 180 Day Track
S007 2015-01-26 Real-time Process
S006 2015-01-26 Real-time Process
S005 2015-01-21 30-day Notice
S004 2015-01-21 30-day Notice
S003 2014-12-22 30-day Notice
S002 2014-12-15 30-day Notice
S001

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.